Stocks making the biggest moves after hours: Cisco, Bath & Body Works, Synopsys

Stocks making the biggest moves after hours: Cisco, Bath & Body Works, Synopsys


A man passes under a Cisco logo at the Mobile World Congress in Barcelona, Spain February 25, 2019.

Sergio Perez | Reuters

Check out the companies making headlines after the bell

Cisco Systems — Shares of the networking company sank nearly 13% after hours as the company forecasted a surprising decline in revenue for the current quarter. Cisco also missed revenue expectations in its fiscal third quarter. The company posted an adjusted profit of 87 cents per share versus the Refinitiv consensus estimate of 86 cents per share.

Bath & Body Works — The retailer saw shares fall more than 5% in extended trading after forecasting lower-than-expected second-quarter earnings. Bath & Body Works did, however, beat Wall Street estimates on the top and bottom lines in its first quarter. The company posted earnings of 64 cents per share on revenue of $1.45 billion. Analysts were expecting earnings of 53 cents per share on revenue of $1.43 billion, according to Refinitiv.

Synopsys — The software stock rose 4% in after-hours trading after the company reported3an earnings beat. The company posted an adjusted quarterly profit of $2.50 per share on revenue of $1.28 billion. Analysts surveyed by StreetAccount were expecting a profit of $2.37 per share on revenue of $1.26 billion.



Source

This bargain fintech stock is stuck in a five-year rut. A turnaround is coming
Finance

This bargain fintech stock is stuck in a five-year rut. A turnaround is coming

Source

Read More
Stocks making the biggest moves premarket: AstraZeneca, Unity Software, Coinbase & more
Finance

Stocks making the biggest moves premarket: AstraZeneca, Unity Software, Coinbase & more

Check out the companies making the biggest moves premarket: AstraZeneca — The pharma giant rose 3% after its experimental drug, tozorakimab, was found to meaningfully reduce flare-ups in cases of chronic obstructive pulmonary disease. The drug delivered the results in two late-stage trials, and the company said full results will be delivered at an upcoming […]

Read More
Why one hedge fund veteran is urging investors to ‘prepare for the worst’
Finance

Why one hedge fund veteran is urging investors to ‘prepare for the worst’

ETF Edge Why one hedge fund veteran is urging investors to ‘prepare for the worst’ Published Fri, Mar 27 20267:00 AM EDT Blair Bao WATCH LIVE Source

Read More